Header Logo

Connection

Frederick Raal to Cholesterol, LDL

Back to Details
This is a "connection" page, showing publications Frederick Raal has written about Cholesterol, LDL.
Frederick Raal
Connection Strength
21,583
Cholesterol, LDL
  1. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
    View in: PubMed
    Score: 0,836
  2. Heart groups in South Africa advocate for tighter LDL-C control and lipoprotein(a) testing to curb atherosclerotic cardiovascular disease. S Afr Med J. 2024 May 09; 114(5):e1973.
    View in: PubMed
    Score: 0,826
  3. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
    View in: PubMed
    Score: 0,820
  4. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther. 2024 Jun; 38(3):493-503.
    View in: PubMed
    Score: 0,751
  5. New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors. S Afr Med J. 2020 Oct 28; 110(11):13126.
    View in: PubMed
    Score: 0,647
  6. Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2747-2755.
    View in: PubMed
    Score: 0,640
  7. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Cardiovasc J Afr. 2020 Sep/Oct; 31(5):245-251.
    View in: PubMed
    Score: 0,640
  8. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 08 20; 383(8):711-720.
    View in: PubMed
    Score: 0,639
  9. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation. 2020 06 02; 141(22):1829-1831.
    View in: PubMed
    Score: 0,629
  10. Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. Cardiovasc J Afr. 2019 Sep/Oct 23; 30(5):279-284.
    View in: PubMed
    Score: 0,598
  11. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther. 2019 02; 33(1):69-76.
    View in: PubMed
    Score: 0,574
  12. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018 10; 277:483-492.
    View in: PubMed
    Score: 0,560
  13. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis. 2018 10; 277:502-507.
    View in: PubMed
    Score: 0,560
  14. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017 06 01; 2(6):598-607.
    View in: PubMed
    Score: 0,511
  15. Glycaemic, blood pressure and cholesterol control in 25 629 diabetics. Cardiovasc J Afr. 2015 Jul-Aug; 26(4):188-92.
    View in: PubMed
    Score: 0,447
  16. New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metab Clin North Am. 2014 Dec; 43(4):1007-33.
    View in: PubMed
    Score: 0,430
  17. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014; 65:417-31.
    View in: PubMed
    Score: 0,403
  18. Targeting LDL: is lower better and is it safe? Best Pract Res Clin Endocrinol Metab. 2014 Jun; 28(3):309-24.
    View in: PubMed
    Score: 0,399
  19. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 05; 128(19):2113-20.
    View in: PubMed
    Score: 0,394
  20. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc. 2013 Apr 24; 2(2):e000028.
    View in: PubMed
    Score: 0,384
  21. Polygenic familial hypercholesterolaemia: does it matter? Lancet. 2013 Apr 13; 381(9874):1255-7.
    View in: PubMed
    Score: 0,380
  22. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012 Nov 13; 126(20):2408-17.
    View in: PubMed
    Score: 0,372
  23. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011 Nov 15; 124(20):2202-7.
    View in: PubMed
    Score: 0,345
  24. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar 20; 375(9719):998-1006.
    View in: PubMed
    Score: 0,310
  25. Questioning the importance of LDL cholesterol: don't throw the baby out with the bathwater! Cardiovasc J Afr. 2008 Mar-Apr; 19(2):63-4.
    View in: PubMed
    Score: 0,269
  26. Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):178-187.
    View in: PubMed
    Score: 0,217
  27. Homozygous Familial Hypercholesterolemia Treatment: New Developments. Curr Atheroscler Rep. 2025 Jan 03; 27(1):22.
    View in: PubMed
    Score: 0,216
  28. Ezetimibe in the management of homozygous familial hypercholesterolaemia. J Clin Lipidol. 2025 Mar-Apr; 19(2):320-326.
    View in: PubMed
    Score: 0,214
  29. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug; 26(8):3223-3237.
    View in: PubMed
    Score: 0,207
  30. A single-centre retrospective observational study to evaluate the change in total cholesterol and LDL cholesterol in hyperlipidaemic patients switched from atorvastatin to simvastatin. Cardiovasc J S Afr. 2004 May-Jun; 15(3):118-23.
    View in: PubMed
    Score: 0,206
  31. The South African Lipid Guidelines: is there a need for an update? Cardiovasc J S Afr. 2004 Mar-Apr; 15(2):53-4.
    View in: PubMed
    Score: 0,204
  32. Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment. Ann Med. 2023 12; 55(1):2199218.
    View in: PubMed
    Score: 0,200
  33. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2023 11 30; 30(17):1874-1880.
    View in: PubMed
    Score: 0,200
  34. Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor. S Afr Med J. 2023 Nov 06; 113(11):35-40.
    View in: PubMed
    Score: 0,199
  35. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation. 2024 01 30; 149(5):354-362.
    View in: PubMed
    Score: 0,199
  36. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis. Curr Atheroscler Rep. 2022 12; 24(12):959-967.
    View in: PubMed
    Score: 0,186
  37. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. S Afr Med J. 2022 05 31; 112(6):426-432.
    View in: PubMed
    Score: 0,181
  38. Evolocumab in patients with homozygous familial hypercholesterolemia in India. J Clin Lipidol. 2021 Nov-Dec; 15(6):814-821.
    View in: PubMed
    Score: 0,173
  39. Novel therapies for familial hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes. 2021 04 01; 28(2):188-195.
    View in: PubMed
    Score: 0,167
  40. Never too old to benefit from lipid-lowering treatment. Lancet. 2020 11 21; 396(10263):1608-1609.
    View in: PubMed
    Score: 0,162
  41. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 04 16; 382(16):1507-1519.
    View in: PubMed
    Score: 0,155
  42. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 04 16; 382(16):1520-1530.
    View in: PubMed
    Score: 0,155
  43. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. J Am Coll Cardiol. 2020 02 18; 75(6):565-574.
    View in: PubMed
    Score: 0,154
  44. Familial hypercholesterolaemia workshop for leveraging point-of-care testing and personalised medicine in association with the Lipid and Atherosclerosis Society of Southern Africa. Cardiovasc J Afr. 2019 Sep/Oct; 30(5):297-304.
    View in: PubMed
    Score: 0,149
  45. Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. J Clin Lipidol. 2019 Sep - Oct; 13(5):735-743.
    View in: PubMed
    Score: 0,147
  46. Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol. 1999 May 01; 83(9):1330-3.
    View in: PubMed
    Score: 0,146
  47. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovasc J Afr. 2019 Jan/Feb 23; 30(1):15-23.
    View in: PubMed
    Score: 0,143
  48. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct; 41(10):1328-1335.
    View in: PubMed
    Score: 0,141
  49. Fibroblast growth factor-23 in patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2018 May - Jun; 12(3):767-772.
    View in: PubMed
    Score: 0,134
  50. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol. 2017 11; 24(17):1843-1850.
    View in: PubMed
    Score: 0,130
  51. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol. 2017 Aug 29; 70(9):1162-1170.
    View in: PubMed
    Score: 0,130
  52. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017 04; 5(4):280-290.
    View in: PubMed
    Score: 0,125
  53. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016 Oct; 30(5):473-483.
    View in: PubMed
    Score: 0,122
  54. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016 06; 57(6):1086-96.
    View in: PubMed
    Score: 0,118
  55. Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis. 2016 May; 248:238-44.
    View in: PubMed
    Score: 0,117
  56. Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther. 2016 Feb; 30(1):101-8.
    View in: PubMed
    Score: 0,116
  57. Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Curr Cardiol Rep. 2015 Nov; 17(11):104.
    View in: PubMed
    Score: 0,114
  58. Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. Arterioscler Thromb Vasc Biol. 2015 Nov; 35(11):2269-80.
    View in: PubMed
    Score: 0,113
  59. Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolaemia. Atherosclerosis. 1995 May; 115(1):9-15.
    View in: PubMed
    Score: 0,111
  60. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1489-99.
    View in: PubMed
    Score: 0,110
  61. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9.
    View in: PubMed
    Score: 0,110
  62. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):331-40.
    View in: PubMed
    Score: 0,106
  63. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):341-50.
    View in: PubMed
    Score: 0,106
  64. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol. 2015 Jul; 22(7):849-54.
    View in: PubMed
    Score: 0,103
  65. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014 Apr 08; 63(13):1278-1288.
    View in: PubMed
    Score: 0,101
  66. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol. 2014 Mar-Apr; 8(2):148-72.
    View in: PubMed
    Score: 0,101
  67. Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS). Cardiovasc J Afr. 2013 Sep; 24(8):330-8.
    View in: PubMed
    Score: 0,098
  68. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012 Aug; 223(2):262-8.
    View in: PubMed
    Score: 0,089
  69. CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia. Cardiovasc J Afr. 2011 Sep-Oct; 22(5):234-40.
    View in: PubMed
    Score: 0,086
  70. The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG). Cardiovasc J Afr. 2008 Mar-Apr; 19(2):88-94.
    View in: PubMed
    Score: 0,067
  71. Postprandial lipaemia, metabolic syndrome and LDL particle size in urbanised South African blacks with and without coronary artery disease. QJM. 2008 Feb; 101(2):111-9.
    View in: PubMed
    Score: 0,067
  72. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr. 2007 Sep-Oct; 18(5):325-9.
    View in: PubMed
    Score: 0,065
  73. Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry. Eur Heart J. 2025 Mar 24; 46(12):1127-1140.
    View in: PubMed
    Score: 0,055
  74. Obesity phenotypes and dyslipidemia in adults from four African countries: An H3Africa AWI-Gen study. PLoS One. 2025; 20(1):e0316527.
    View in: PubMed
    Score: 0,054
  75. Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2024 Dec 14; 404(10470):2462-2475.
    View in: PubMed
    Score: 0,054
  76. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. Lancet Child Adolesc Health. 2024 Jul; 8(7):491-499.
    View in: PubMed
    Score: 0,052
  77. Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia. JAMA Cardiol. 2024 Apr 01; 9(4):313-322.
    View in: PubMed
    Score: 0,051
  78. Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention. Atherosclerosis. 2024 Apr; 391:117472.
    View in: PubMed
    Score: 0,051
  79. Safety and Tolerability of Inclisiran for?Treatment of Hypercholesterolemia in?7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
    View in: PubMed
    Score: 0,050
  80. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis. 2023 12; 386:117354.
    View in: PubMed
    Score: 0,050
  81. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023 Jul 01; 44(25):2277-2291.
    View in: PubMed
    Score: 0,049
  82. Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19. Curr Opin Lipidol. 2023 06 01; 34(3):119-125.
    View in: PubMed
    Score: 0,048
  83. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 01 07; 44(2):129-138.
    View in: PubMed
    Score: 0,047
  84. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022 12 21; 43(48):5047-5057.
    View in: PubMed
    Score: 0,047
  85. Non-HDL-C and LDL-C/HDL-C are associated with self-reported cardiovascular disease in a rural West African population: Analysis of an array of lipid metrics in an AWI-Gen sub-study. PLoS One. 2022; 17(12):e0278375.
    View in: PubMed
    Score: 0,047
  86. Familial Hypercholesterolemia Identification by Machine Learning Using Lipid Profile Data Performs as Well as Clinical Diagnostic Criteria. Circ Genom Precis Med. 2022 10; 15(5):e003324.
    View in: PubMed
    Score: 0,046
  87. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022 10; 10(10):732-740.
    View in: PubMed
    Score: 0,046
  88. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug; 16(4):538-543.
    View in: PubMed
    Score: 0,045
  89. Quantity versus quality of LDL cholesterol in patients with familial hypercholesterolemia--which is more important? Clin Chim Acta. 2001 Dec; 314(1-2):167-73.
    View in: PubMed
    Score: 0,044
  90. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021 05; 325:46-56.
    View in: PubMed
    Score: 0,042
  91. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 03 09; 77(9):1182-1193.
    View in: PubMed
    Score: 0,041
  92. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020 06 21; 41(24):2313-2330.
    View in: PubMed
    Score: 0,039
  93. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000 Jun; 150(2):421-8.
    View in: PubMed
    Score: 0,039
  94. Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol. 1999 Dec 01; 84(11):1344-6, A7.
    View in: PubMed
    Score: 0,038
  95. South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). S Afr Med J. 2018 10 26; 108(11b):973-1000.
    View in: PubMed
    Score: 0,035
  96. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018 10; 277:234-255.
    View in: PubMed
    Score: 0,035
  97. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
    View in: PubMed
    Score: 0,033
  98. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997 Dec; 135(2):249-56.
    View in: PubMed
    Score: 0,033
  99. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017 Nov - Dec; 11(6):1448-1457.
    View in: PubMed
    Score: 0,033
  100. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21; 38(32):2459-2472.
    View in: PubMed
    Score: 0,032
  101. CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolaemia among South African Indians. Clin Genet. 1997 Jun; 51(6):394-8.
    View in: PubMed
    Score: 0,032
  102. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. Atherosclerosis. 1997 Feb 28; 129(1):97-102.
    View in: PubMed
    Score: 0,031
  103. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016 10; 4(10):850-61.
    View in: PubMed
    Score: 0,030
  104. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2016 08; 36(8):1647-50.
    View in: PubMed
    Score: 0,030
  105. Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb. 2016 May 02; 23(5):567-87.
    View in: PubMed
    Score: 0,029
  106. Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J Clin Lipidol. 2015 Mar-Apr; 9(2):201-9.
    View in: PubMed
    Score: 0,027
  107. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21; 35(32):2146-57.
    View in: PubMed
    Score: 0,026
  108. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014 Jan 14; 129(2):234-43.
    View in: PubMed
    Score: 0,025
  109. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec; 34(45):3478-90a.
    View in: PubMed
    Score: 0,025
  110. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010 Feb; 156(2):231-6.e1-3.
    View in: PubMed
    Score: 0,019
  111. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008 Mar; 197(1):400-6.
    View in: PubMed
    Score: 0,016
  112. Metabolic syndrome, undiagnosed diabetes mellitus and insulin resistance are highly prevalent in urbanised South African blacks with coronary artery disease. Cardiovasc J S Afr. 2006 Mar-Apr; 17(2):50-5.
    View in: PubMed
    Score: 0,015
  113. Auto-antibodies against oxidized LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann Clin Biochem. 2000 Mar; 37 ( Pt 2):174-8.
    View in: PubMed
    Score: 0,010
  114. Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. Arterioscler Thromb. 1993 Jul; 13(7):1076-81.
    View in: PubMed
    Score: 0,006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.